Benzinga - As the world watches tech titans Elon Musk and Mark Zuckerberg prepare for an unexpected boxing match, Musk’s slimmed-down physique has caught attention. This transformation is attributed to his use of Wegovy, a semaglutide medication used for chronic weight management, Fast Company reports.
Weight Loss Medications in the Spotlight
Drugs like Wegovy and Ozempic are primarily intended for diabetes patients but have gained popularity off-label for weight loss. This trend has led to shortages for diabetic patients who need them. The attention these drugs have garnered has also sparked developments in the weight loss medication space.
New Developments
A pill form of Ozempic was presented at the American Diabetes Association’s annual conference. This new form, which would be taken daily instead of weekly, showed promising results in reducing weight and improving blood sugar levels. However, it may still be a year or two before this pill becomes available due to ongoing trials.
Future Prospects
Another potential breakthrough is a drug called retatrutide, which has shown results comparable to weight-loss surgeries. However, it too needs to go through phase 3 trials before it can hit the market.
Insurance Coverage
Telemedicine companies like Found are working with employers to offer weight-management benefits to their employees, including prescriptions for drugs like Ozempic. However, the high cost of these drugs presents a challenge. Dr. Angela Fitch, founder and chief medical officer of Knownwell, argues that access to these obesity treatments should be offered by Medicaid and Medicare, rather than through employers.
Read More: Australia’s Eucalyptus Adds Ozempic To Weight-Loss Drug Lineup After Initial Resistance
Hi, I am the Benzinga Newsbot!
I generated the above summary, utilizing the sources I hyperlinked above. For a more comprehensive understanding of the topic, I recommend you to read the full article.
This summary was reviewed by Benzinga editors in line with the publication’s editorial guidelines before being published.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
